A new trading day began on Friday, with Intellia Therapeutics Inc (NASDAQ: NTLA) stock price up 7.84% from the previous day of trading, before settling in for the closing price of $13.65. NTLA’s price has ranged from $12.82 to $34.87 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 12.09% over the last five years. Meanwhile, its annual earnings per share averaged 1.95%. With a float of $100.10 million, this company’s outstanding shares have now reached $101.80 million.
The firm has a total of 526 workers. Let’s measure their productivity. In terms of profitability, gross margin is 82.41%, operating margin of -1247.99%, and the pretax margin is -1212.19%.
Intellia Therapeutics Inc (NTLA) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Intellia Therapeutics Inc is 1.72%, while institutional ownership is 92.40%. The most recent insider transaction that took place on Oct 02 ’24, was worth 38,248. In this transaction VP, Chief Accounting Officer of this company sold 2,012 shares at a rate of $19.01, taking the stock ownership to the 47,012 shares. Before that another transaction happened on Jul 01 ’24, when Company’s EVP, Chief Technical Officer sold 405 for $22.93, making the entire transaction worth $9,287. This insider now owns 71,470 shares in total.
Intellia Therapeutics Inc (NTLA) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 1.95% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 30.00% during the next five years compared to -22.30% drop over the previous five years of trading.
Intellia Therapeutics Inc (NASDAQ: NTLA) Trading Performance Indicators
Here are Intellia Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 6.73. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 37.52.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.45, a number that is poised to hit -1.34 in the next quarter and is forecasted to reach -5.50 in one year’s time.
Technical Analysis of Intellia Therapeutics Inc (NTLA)
Analysing the last 5-days average volume posted by the [Intellia Therapeutics Inc, NTLA], we can find that recorded value of 2.28 million was better than the volume posted last year of 1.76 million. As of the previous 9 days, the stock’s Stochastic %D was 31.71%. Additionally, its Average True Range was 1.01.
During the past 100 days, Intellia Therapeutics Inc’s (NTLA) raw stochastic average was set at 12.71%, which indicates a significant decrease from 59.56% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 69.30% in the past 14 days, which was higher than the 68.10% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $16.73, while its 200-day Moving Average is $22.46. Now, the first resistance to watch is $15.15. This is followed by the second major resistance level at $15.59. The third major resistance level sits at $16.29. If the price goes on to break the first support level at $14.01, it is likely to go to the next support level at $13.31. Should the price break the second support level, the third support level stands at $12.87.
Intellia Therapeutics Inc (NASDAQ: NTLA) Key Stats
With a market capitalization of 1.62 billion, the company has a total of 101,849K Shares Outstanding. Currently, annual sales are 36,280 K while annual income is -481,190 K. The company’s previous quarter sales were 9,110 K while its latest quarter income was -135,710 K.
